Post Marketing Surveillance to Observe Safety and Effectiveness of CABOMETYX™ in Korea.
About the study
The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyx™ in real clinical practice setting, according to the approved labelling after the approval of marketing authorization.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Patients who meet 'Indications' of label for Cabometyx™ as monotherapy
- Patients who are treated with Cabometyx™ for the first time according to label for Cabometyx™ as monotherapy
- Patients who are aged 18 years or older
- Patients who are willing to provide written consent after being informed of this surveillance
EXCLUSION CRITERIA
Exclusion Criteria:
Patients who are contraindicated for Cabometyx™ based on Cabometyx™ label
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Renal Cell Carcinoma,Hepatocellular Carcinoma
Age (in years)
18+
Participants Needed
333
Est. Completion Date
Jun 30, 2024
Treatment Type
Observational
Sponsor
Ipsen
ClinicalTrials.gov NCT Identifier
NCT03776123
Study Number
A-KR-60000-021
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?